Join new study on CRPS
For those with chronic pain and have a diagnosis of either CRPS Type I or II there is a study you can join. A PhD. Candidate from the University off Iowa is conducting research on the reduction of quality of life from CRPS. The study is being underwritten by the Reflex Sympathetic Dystrophy Association which is well known for it’s work on chronic pain issues. To be eligible you must have CRPS but cannot have other pain issues or conditions, be between the ages of 18-89 and agree to give out your medical history. There is a document that yo u will need to read that explains the study in detail so you can make a decision if this study is for you. Assuming you agree to the document, will be asked to fill out an on-line survey that will take about 20 minutes to complete. Here is the link to the study.
Studies are an important part of medicine that allow doctors and researchers to understand how different therapies work and if they are safe over time for particular age groups. The only way that drugs and therapies for chronic pain is we help the research community help us. Unless there is something in the study that would dramatically impact your life in a negative way, please sign up. The more people that agree to help, the more statistically significant the study will be. Larger groups help to show problems quickly and can help to create the contraindications list that we get on all our prescription drugs. The medical information is protected by HIPAA guidelines which are a set of federal laws that keep unauthorized people from accessing your data or selling it to another entity.
Most of us will never get the chance to help ourselves or others in medicine. We work with our doctors and together a plan is developed on the best course of action and which drugs to take. Please take this opportunity to make medicine safer and more effective. Together we can make things better a little bit at a time.
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.







User Comments
No comments yet.
Sorry, the comment form is closed at this time.